Raymond James Financial
NKTR icon

Raymond James Financial’s Nektar Therapeutics NKTR Stock Holding History

Raymond James Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$212K Buy
+2,953
New +$168K ﹤0.01% 4857
2025
Q3 		– Sell
-313
Closed -$8.09K – 6108
2025
Q2 		$8.09K Buy
+313
New +$3.51K ﹤0.01% 6007

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Raymond James Financial's NKTR Position: Q1 2026 in Review

Raymond James Financial opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 2,953 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #4857 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in NKTR as recently as Q2 2025.

Raymond James Financial first reported a position in NKTR in Q2 2025 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Raymond James Financial held 2,953 shares of Nektar Therapeutics worth $212K as of Q1 2026.
  • Nektar Therapeutics was a new Raymond James Financial position in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4857 holding.
  • Raymond James Financial first reported a position in Nektar Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.